MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1200/op.20.00117

Медицинская библиотека · JCO oncology practice · 2020

Evaluation of Omics-Based Strategies for the Management of Advanced Lung Cancer.

Salgia Ravi, Mambetsariev Isa, Pharaon Rebecca, Fricke Jeremy, Baroz Angel Ray, Hozo Iztok, Chen Chen, Koczywas Marianna, Massarelli Erminia, Reckamp Karen, Djulbegovic Benjamin

СтатьяПоддержка NIH: внешняя программаПеревод пока не подготовлен

Аннотация

PURPOSE: Omic-informed therapy is being used more frequently for patients with non-small-cell lung cancer (NSCLC) being treated on the basis of evidence-based decision-making. However, there is a lack of a standardized framework to evaluate those decisions and understand the association between omics-based management strategies and survival among patients. Therefore, we compared outcomes between patients with lung adenocarcinoma who received omics-driven targeted therapy versus patients who received standard therapeutic options.

PATIENTS AND

METHODS

This was a retrospective study of patients with advanced NSCLC adenocarcinoma (N = 798) at City of Hope who received genomic sequencing at the behest of their treating oncologists. A thoracic oncology registry was used as a clinicogenomic database to track patient outcomes.

RESULTS

Of 798 individuals with advanced NSCLC (median age, 65 years [range, 22-99 years]; 60% white; 50% with a history of smoking), 662 patients (83%) had molecular testing and 439 (55%) received targeted therapy on the basis of the omic-data. A fast-and-frugal decision tree (FFT) model was developed to evaluate the impact of omics-based strategy on decision-making, progression-free survival (PFS), and overall survival (OS). We calculated that the overall positive predictive value of the entire FFT strategy for predicting decisions regarding the use of tyrosine kinase inhibitor-based targeted therapy was 88% and the negative predictive value was 96%. In an adjusted Cox regression analysis, there was a significant correlation with survival benefit with the FFT omics-driven therapeutic strategy for both PFS (hazard ratio [HR], 0.56; 95% CI, 0.42 to 0.74; P < .001) and OS (HR, 0.51; 95% CI, 0.36 to 0.71; P < .001) as compared with standard therapeutic options.

CONCLUSION

Among patients with advanced NSCLC who received care in the academic oncology setting, omics-driven therapy decisions directly informed treatment in patients and was correlated with better OS and PFS.

Для цитирования: Salgia Ravi, Mambetsariev Isa, Pharaon Rebecca, Fricke Jeremy, Baroz Angel Ray, Hozo Iztok, Chen Chen, Koczywas Marianna, Massarelli Erminia, Reckamp Karen, Djulbegovic Benjamin. Evaluation of Omics-Based Strategies for the Management of Advanced Lung Cancer.. JCO oncology practice. 2020. DOI: 10.1200/op.20.00117.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.